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Rezultatele studiului clinic randomizat „dublu-orb”, placebo-controlat au confirmat faptul că includerea modifica-
torului leucotrienelor Montelukast (Zespira®) în tratamentul complex de bază la copiii cu astm bronșic cu severitatea 
moderată, asigură un efect clinic aditiv, ceea ce permite obţinerea controlului asupra astmului bronșic la 75,0±6,8% 
din pacienţi (comparativ cu 47,0±7,9% la copiii cu monoterapie 200 µg de Fluticazonă (Flixotide®, p<0,01).
РЕЗЮМЕ
АНТИЛЕЙКОТРИЕНЫ В ЛЕЧЕНИИ ПЕДИАТРИЧЕСКОЙ АСТМЫ:  
ЭФФЕКТИВНОСТЬ «ADD-ON» ТЕРАПИИ
Ключевые слова: дети, астма, кортикостероиды, антилейкотриенs, эффективность
В ходе двойного „слепого”, плацебо-контролируемого клинического испытания было доказано, что 
подключение модификатора лейкотриенов Montelukast (Zespira®) в комплекс базисной терапии детей с БА 
среднетяжелого течения обеспечивает аддитивный клинический эффект, что позволяет достичь полный 
астма-контроль у 75,0±6,8% пациентов (по-сравнению с 47,0±7,9% на фоне 200 мкг/кг Фликсотида, p<0,01). 
Introduction. Asthma is a heterogeneous disease, usually 
characterized by chronic airway inflammation (GINA). 
The „golden standard” of asthma control in children is 
inhaled corticosteroids (ICS) [2]. However, multicenter 
epidemiological studies (GOAL, AIRE, INSPIRE) indi-
cate failure of asthma control in the vast majority of 
patients (approx. 70%). There is ample reliable published 
data on the antiasthmatic efficiency and safety of leukot-
riene receptor antagonists (LTRA) (MOSAIC, et al) [3, 
4]. However, LTRA have no anti-inflammatory effect. 
The character of interaction of LTRA with ICS is not fully 
determined. Our earlier research indicates that the level 
of LTC4 in exacerbations of asthma in children increases 
10 times (31.0±0.9 ng/ml versus 2.2±0.2 ng/ml in the 
control group, p<0.001) [5]. Therefore, add-on therapy 
could be sufficient to achieve asthma control without 
increasing the dose of corticosteroids [1, 3, 4]. 
Objective/Aim: Explore the additive effect of the antileu-
cotriene Montelukast (Zespira®) in children with mild-to-
moderate asthma. 
Methodology. This is 12-week, placebo-controlled, 
double blind, randomized trial in parallel groups (ZPA-
007-01) in 40 children, aged 5-15 years, with mild-to-
moderate asthma and poor symptom control despite 2 
weeks of treatment (run-in period) with low dose of ICS 
(Fluticasone propionate ≤200µg daily). 
The study used LTRA Montelukast sodium 5 mg 
(Zespira®, produced by „Bilim Pharmaceuticals”, Turkey). 
Identically looking and packaged tablets (produced by 
„Farmaco”, Moldova) were used as Placebo. According to 
the add-on design, all patients continued treatment with 
ICS Fluticasone 100 µg twice daily and used short-acting 
beta2-agonist (SABA) „as-needed”. The response profile 
was estimated after 4, 8 and 12 weeks by: 
• Assessing asthma symptom control (number of 
exacerbations, daytime asthma symptoms, nocturnal 
awakenings, reliever needed, percentage of asth-
ma-free days); 
• Lung function testing (spirometry); 
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• Assessing safety and tolerance (complaints, transami-
nases AST, ALT). 
Protocol of clinical trial was sanctioned by the National 
Ethics Committee of RM. Patients’ parents signed the 
Informed Consent beforehand. 
Statistical analysis was done with the use of EpiInfo 3.5 
and RevMan 5.0 (ANOVA, Fisher’s exact test, Cochran-
Mantel-Haenszel test). 
Results. Assessing asthma symptom control. After 4 
weeks of treatment with Montelukast+ICS the following 
were significantly reduced from baseline: asthma symp-
toms (p<0.05), percentage of asthma-free days (p<0.01) 
and, coresponding, use of SABA (p<0.01), fig. 1, 2. 
Fig.1. Frequency of asthma symptoms (daily and nighttime 
symptoms /month)
Fig.2 „As-needed” SABA use (puffs/month )
After 12 weeks of treatment with Montelukast+ICS the 
following have dropped: 
• the frequency of daytime asthma symptoms – 3 times 
from baseline (p<0.05) 
• the frequency of nocturnal awakenings – 4 times 
(p<0.001) 
• the need for bronchodilators – 3 times (p<0.01). 
While asthma-free days increased nearly 2 times 
(p<0.001). 
In the Placebo+ICS group significant diffrence from base-
line has not been noted (p>0.05) 
The impact on the lung func-
tion. Montelukast together with 
inhaled corticosteroids, possesses 
a pronounced additive effect, 
certainly improving lung func-
tion in children with mild-to-
moderate asthma. During the 
12-week period the average 
increase of dynamic parameters of spirometry was 
20-30%, in comparison with 3-7% in Placebo+ICS group 
(p<0.05), fig. 3. 
Fig.3 Percentage of change inf spirometry parameters (%)
After 12 weeks of treatment with Montelukast 2/3 of chil-
dren had normal values of pulmonary function (>80% of 
predicted) in comparison with the 35.0% at the begin-
ning (p<0.05). 
Out of the monotherapy with ICS group only 1/3 of 
children had normal lung function at the end of study 
(in comparison with 17.6% at the beginning, p>0.05; in 
comparison with Montelukast+ICS group – p<0.05). 
As a result, complete asthma control (according to inter-
national protocol GINA) was achieved in 75% of patients 
who underwent Montelukast together with ICS, in 
comparison with the 47% among those who underwent 
monotherapy with ICS (p<0.01). 
Thus, alongside therapy with LTRA Montelukast in chil-
dren with mild-to-moderate asthma and poor symptom 
control on treatment with low dose of ICS induction 
of clinical improvement was noticeable already during 
the first days of treatment, reaching its peak on the 8th 
week and remaining stable. The phenomenon of ther-
apeutic selectivity was observed: in 15% of children on 
combination therapy with Montelukast asthma symp-
toms disappeared completely after 4 weeks and asthma 
control was maintained with only ¼ of initial doses of 
ICS (Fluticasone 50 µg/day), however, 25% of patients 
did not attain asthma control after 12 weeks of combina-
tion Montelukast with Fluticasone 200 µg daily. 
To strengthen the statistical significance and to posi-
tion our research among similar studies we ran a meta-
analysis (Cochrane unique ID: 713209011917161246). 
Using evidence-based data sources we have identified 31 
paediatric studies on effectiveness of additive treatment 
with antileucotrienes (yrs. 1996–2007), 10% were consid-
ered eligible based on methodological compatibility with 
our research. Endpoint: number of exacerbations. The 
sample size – 1108 children. The methodological quality 
of included studies (GRADE) was ≥4 (Jadad, 1996). 
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Thus, additive treatment with the use of the antileuco-
triene Montelukast in children with asthma leads to a 
double reduction in number of exacerbations (RR=0.45; 
95%CI:0.30-0.65; p<0.0001).
Conclision. The data collected in the randomized trial and 
the statistics from the meta-analysis, demonstrate that 
the efficiency and safety of Montelukast (Zespira®) allows 
for it to be recommended as a controller medication for 
children with mild-to-moderate persistent asthma in 
combination with inhaled corticosteroids as a „add-on 
therapy”. The question for following studies: what asth-
ma-phenotype in children is the most sensitive to anti-
leukotrienes? 
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